Discover
KROS
Keros Therapeutics, Inc.
10.10
1 x 9.95
2 x 10.25
bid
ask
-
0.56
5.25%
undefined @ 04:00 PM
10.10 +0.00 (0.00%)
| Ytd | -50.39% | |
| 1y | -29.96% |
10.02
day range
10.59
9.69
52 week range
22.55
| Open | 10.59 | Prev Close | 10.66 | Low | 10.02 | High | 10.59 | Mkt Cap | 323.18M |
| Vol | 315.07K | Avg Vol | 271.89K | EPS | -3.70 | P/E | -2.73 | Forward P/E | -3.00 |
| Beta | 1.24 | Short Ratio | 5.28 | Inst. Own | 100.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 10.62 | 200-d Avg | 14.06 | 1yr Est | 43.55 |
| Income Statement | |||
| Operating Expenses | 30.94M | ||
| Research and Development Expense | 22.33M | ||
| Selling, General and Administrative Expense | 8.61M | ||
| Operating Income | -30.94M | ||
| Net Income | -28.71M | ||
| Net Income Common Stock | -28.71M | ||
| Net Income Common Stock (USD) | -28.71M | ||
| Consolidated Income | -28.71M | ||
| Earnings per Basic Share | -1.45 | ||
| Earnings per Basic Share (USD) | -1.45 | ||
| Earnings per Diluted Share | -1.45 | ||
| Earning Before Interest & Taxes (EBIT) | -28.71M | ||
| Earning Before Interest & Taxes (USD) | -28.71M | ||
| Weighted Average Shares | 19.80M | ||
| Weighted Average Shares Diluted | 19.80M | ||
| Balance Sheet | |||
| Cash and Equivalents | 259.06M | ||
| Cash and Equivalents (USD) | 259.06M | ||
| Current Assets | 266.88M | ||
| Property, Plant & Equipment Net | 19.27M | ||
| Total Assets | 287.60M | ||
| Debt Current | 2.60M | ||
| Total Debt | 15.72M | ||
| Current Liabilities | 12.15M | ||
| Debt Non-Current | 13.13M | ||
| Total Liabilities | 25.28M | ||
| Accumulated Retained Earnings (Deficit) | -534.18M | ||
| Shareholders Equity | 262.32M | ||
| Shareholders Equity (USD) | 262.32M | ||
| Assets Non-Current | 20.72M | ||
| Total Debt (USD) | 15.72M | ||
| Liabilities Non-Current | 13.13M | ||
| Trade and Non-Trade Payables | 1.82M | ||
| Tax Assets | 2.25M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.05M | ||
| Net Cash Flow from Financing | -3.31M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -23.89M | ||
| Capital Expenditure | -155.00K | ||
| Issuance (Purchase) of Equity Shares | 23.00K | ||
| Net Cash Flow from Investing | -155.00K | ||
| Net Cash Flow from Operations | -20.42M | ||
| Share Based Compensation | 5.38M | ||